摘要
肿瘤坏死因子(TNF)超家族(TNFSF)包括有关三十个结构相关的受体(TNFSFRs)和绑定到一个或多个这些受体的大约二十个蛋白质配体。几乎所有这些细胞表面蛋白质相互作用(PPIs)代表高价值的治疗目标即自身免疫性疾病、移植受体、癌症的炎症反应和免疫调制,还有那些在临床开发的各个阶段的几种生物制剂包括抗体、融合蛋白定位。如果可以解决与小分子的蛋白质相互作用的目标相关的困难,小分子抑制剂或活化剂可以代表可能的替代品。化学合成证明了这种方法的可行性并以确定了大量的肿瘤坏死因子超家族受体-肿瘤坏死因子超家族型PPIs不同的药物研发途径包括CD40-CD40L、 BAFFR-BAFF、TRAIL-DR5和 OX40-OX40L。在此,对相应的结构、信号和药物化学方面简要综述。然而这些小分子调节剂没有到目前为止能确定似乎有足够的前景用于临床上。他们提供验证的证据表明,这些相互作用容易受到小分子调控作用的影响,可以作为识别更有效的和有选择性的备选项的出发点。
关键词: CD40,协同信号,成药性,OX40,肿瘤坏死因子。
图形摘要
Current Drug Targets
Title:TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Volume: 16 Issue: 4
Author(s): Yun Song and Peter Buchwald
Affiliation:
关键词: CD40,协同信号,成药性,OX40,肿瘤坏死因子。
摘要: The tumor necrosis factor (TNF) superfamily (TNFSF) contains about thirty structurally related receptors (TNFSFRs) and about twenty protein ligands that bind to one or more of these receptors. Almost all of these cell surface protein-protein interactions (PPIs) represent high-value therapeutic targets for inflammatory or immune modulation in autoimmune diseases, transplant recipients, or cancers, and there are several biologics including antibodies and fusion proteins targeting them that are in various phases of clinical development. Small-molecule inhibitors or activators could represent possible alternatives if the difficulties related to the targeting of protein-protein interactions by small molecules can be addressed. Compounds proving the feasibility of such approaches have been identified through different drug discovery approaches for a number of these TNFSFR-TNFSF type PPIs including CD40-CD40L, BAFFR-BAFF, TRAIL-DR5, and OX40-OX40L. Corresponding structural, signaling, and medicinal chemistry aspects are briefly reviewed here. While none of these small-molecule modulators identified so far seems promising enough to be pursued for clinical development, they provide proof-of-principle evidence that these interactions are susceptible to small-molecule modulation and can serve as starting points toward the identification of more potent and selective candidates.
Export Options
About this article
Cite this article as:
Yun Song and Peter Buchwald , TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450116666150223115628
DOI https://dx.doi.org/10.2174/1389450116666150223115628 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Triggering of Apoptosis and Pro-Inflammatory Cytokines in NK Cells: Regulation by Cyclosporin A
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Discovery of Potent Bruton’s Tyrosine Kinase Inhibitors Using Ligand Based Modeling
Anti-Cancer Agents in Medicinal Chemistry Comparative Genomics for the Investigation of Autoimmune Diseases
Current Pharmaceutical Design Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Apoptosis and Autoimmune Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Mechanism of the Affinity Interactions between BAFF and Its Peptides by Molecular Simulations
Protein & Peptide Letters Recent Applications of Chemiluminescence Assays in Clinical Immunology
Mini-Reviews in Medicinal Chemistry Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry The Interleukin-17/Interleukin-22 Innate Axis in the Gut as a New Drug Target in Allergic-Inflammatory and Autoimmune Diseases. A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets